CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Allergan, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Allergan, Inc.
Morris Corporate Center III
400 Interpace Parkway
Phone: (862) 261-7000p:862 261-7000 Parsippany, NJ  07054  United States

This company was Merged or Acquired on 3/17/2015.
This company ceased filing statements with the SEC on 3/27/2015.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates through its two business segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces pharmaceutical products, including: ophthalmic products; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products, and urologics products. The medical devices segment produces a range of medical devices, including: breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
-Yes-Yes-YesYes--

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201412/31/2014YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer, Principal Executive Officer David E.Pyott 61 7/1/2013 1/1/1998
President Douglas S.Ingram 52 7/1/2013 11/1/1998
Chief Financial Officer, Executive Vice President - Finance and Business Development James M.Hindman 48 8/18/2014 2/1/1997
11 additional Officers and Directors records available in full report.

Business Names
Business Name
Actavis Acquisition 1 S.à r.l.
Actavis Acquisition 2 S.à r.l.
Actavis Biodesign Ltd.
241 additional Business Names available in full report.

General Information
Stock Exchange: NYSE
Federal Tax Id: 951622442


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 15, 2019